The present invention relates to a method for freezing and preserving a composition comprising a population of neonatal stromal cells (NSCs) and a cryoprotector, characterised in that it comprises a step of freezing the composition at a temperature of between −70° C. and −140° C., then a step of preserving the composition at between −10° C. and −40° C. The present invention also relates to a composition comprising a population of NSCs and a cryoprotector, characterised in that it is preserved at between −10° C. and −40° C., said NSCs being in particular placental NSCs.

The present invention relates to a method for freezing and preserving a composition comprising a population of neonatal stromal cells (NSCs) and a cryoprotector, characterised in that it comprises a step of freezing the composition at a temperature of between −70° C. and −140° C., then a step of preserving the composition at between −10° C. and −40° C. The present invention also relates to a composition comprising a population of NSCs and a cryoprotector, characterised in that it is preserved at between −10° C. and −40° C., said NSCs being in particular placental NSCs.

The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system.

Described herein are compositions and method for autologous adipose tissue grafting. In one embodiment, the composition comprises a recombinant partially ordered polypeptide (Fractomer) or “Fractomer” and adipose tissue from a subject. In one aspect, the Fractomer has the general structure of [(GXGVP).sub.n-α-helix].sub.m, where X can be any amino acid except proline and α-helix is any polyalanine based α-helix having about 5 to 50 Alanine residues. In another aspect, the Fractomer has the structure [(GXGVP).sub.n-GX.sup.1(A).sub.25X.sup.1].sub.m; where X is A or V; X.sup.1 is K or D; n is an integer from 10 to 20; and m is an integer from 4 to 8.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

The present disclosure relates to a herbo-mineral metallic pharmaceutical kit and a process for its preparation. The herbo-mineral metallic pharmaceutical kit comprises Suvarna Bhasmadi Vati (SBV), Mouktikyukta Kamdudha Vati (MKV), Trailokyachintamani Rasa Vati (TCR), Kumari Kalpa Vati (KKV) and Khadirarishta (KHA). The herbo-mineral metallic pharmaceutical kit of the present disclosure can be used for delaying and/or controlling the recurrence or occurrence of breast and/or ovarian cancer in second breast and/or ovary or metastasis. The herbo-mineral metallic pharmaceutical compositions of the kit assist in reducing oxidative stress, improving immune status and quality of life and maintaining a disease-free survival in patients who are genetically predisposed to breast or ovarian cancer.

A method of treating a subject with Hutchinson-Gilford progeria syndrome includes administering to the subject a composition which includes an allogeneic haploidentical adipose tissue-derived stromal vascular fraction (SVF). The an allogeneic haploidentical adipose tissue-derived SVF may be produced by a process including centrifuging an allogeneic haploidentical adipose tissue lipoaspirate to obtain a packed adipose tissue, mixing the packed adipose tissue with collagenase, mincing the packed adipose tissue mixed with the collagenase by using a homogenizer, incubating the minced adipose tissue, centrifuging the incubated adipose tissue to separate and remove the collagenase, and repeating the centrifuging to obtain the stromal vascular fraction.

A method of treating a subject with Hutchinson-Gilford progeria syndrome includes administering to the subject a composition which includes an allogeneic haploidentical adipose tissue-derived stromal vascular fraction (SVF). The an allogeneic haploidentical adipose tissue-derived SVF may be produced by a process including centrifuging an allogeneic haploidentical adipose tissue lipoaspirate to obtain a packed adipose tissue, mixing the packed adipose tissue with collagenase, mincing the packed adipose tissue mixed with the collagenase by using a homogenizer, incubating the minced adipose tissue, centrifuging the incubated adipose tissue to separate and remove the collagenase, and repeating the centrifuging to obtain the stromal vascular fraction.

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood.